# EDGAR Filing Document

**Accession Number:** 0001513818
**File Stem:** 0001437749-23-002609
**Filing Date:** 2023-2
**Character Count:** 15652
**Document Hash:** 38db1a5ec790de582abc76350f27de9b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-23-002609.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 0001437749-23-002609

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 18

**CONFORMED PERIOD OF REPORT**: 20230201

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aravive, Inc.
- **CENTRAL INDEX KEY:** 0001513818
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 264106690
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36361
- **FILM NUMBER:** 23591478

**BUSINESS ADDRESS:**
- **STREET 1:** RIVER OAKS TOWER
- **STREET 2:** 3730 KIRBY DRIVE, SUITE 1200
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77098
- **BUSINESS PHONE:** 936-355-1910

**MAIL ADDRESS:**
- **STREET 1:** RIVER OAKS TOWER
- **STREET 2:** 3730 KIRBY DRIVE, SUITE 1200
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77098

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Versartis, Inc.
- **DATE OF NAME CHANGE:** 20110223

arav20230206_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM **8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): **February 1, 2023**

## Aravive, Inc.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36361** | **26-4106690** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

**River Oaks Tower**

**3730 Kirby Drive, Suite 1200**

**Houston, Texas 77098**

**(Address of principal executive offices)**

**(**936**) 355-1910**

**(Registrant**'**s telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| **Common stock, par value $0.0001 per share** | **ARAV** | **Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.**

Effective February 1, 2023, Aravive, Inc. (the "Company") entered into (i) an amendment (the "McIntyre Amendment"), to the Offer Letter that it had entered into with Gail McIntyre, Ph.D., the Company's Chief Executive Officer, on March 26, 2020, as amended on April 8, 2020 and January 25, 2021 to increase her annual base salary of $560,000; (ii) an amendment (the "Howard Amendment"), to the Offer Letter that it had entered into with Rudy Howard, the Company's Chief Financial Officer, on June 2, 2022 to increase his annual base salary of $412,775; (iii) an amendment to the Offer Letter (the "Geller Offer Letter") that it had entered into with Robert Geller, M.D., the Company's Chief Medical Officer, on June 13, 2022 to increase his annual base salary of $450,000; and (iv) an amendment to the Offer Letter that it had entered into with Leonard Scott Dove, Ph.D. the Company's Chief Operating Officer, on February 20, 2022 to increase his annual base salary of $405,000.

On February 1, 2023, each of Dr. McIntyre, Mr. Howard, Dr. Geller and Dr. Dove were also granted a cash bonus equal to 105% of their target bonus amount for the Company's 2022 fiscal year and options to purchase 700,000, 400,000, 400,000 and 400,000 shares of the Company's common stock, respectively at an exercise price of $1.67 per share and vesting over a three-year period with 50% vesting on the one-year anniversary of the date of grant and the remaining 50% vesting on a pro rata basis on a monthly basis over a two-year period commencing on the month following the one- year anniversary of the grant date.

The foregoing descriptions of the McIntyre Amendment, Howard Amendment, Geller Amendment and Dove Amendment do not purport to be complete and are qualified in their entirety by reference to copy of the McIntyre Amendment, Howard Amendment, Geller Amendment, Dove Amendment, which are filed as Exhibits 10.1, 10.2, 10.3 and 10.4, to this Current Report on Form 8-K and are incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 10.1 | [<u>Amendment No. 3 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Gail McIntyre, Ph.D.</u>](ex_472000.htm) |
| 10.2 | [<u>Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Rudy</u> Howard](ex_472001.htm) |
| 10.3 | [<u>Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Robert Geller, M.D.</u>](ex_472002.htm) |
| 10.4 | [<u>Amendment No. 1 to Offer Letter dated as of February 1, 2023 by and between Aravive, Inc. and Leonard Scott Dove, Ph.D.</u>](ex_472003.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 6, 2023 | **ARAVIVE, INC.**<br> (Registrant) | **ARAVIVE, INC.**<br> (Registrant) |
|  | By: | /s/ Gail McIntyre |
|  | Name: | Gail McIntyre |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

![aravive01.jpg](aravive01.jpg)

River Oaks Tower

3730 Kirby Drive, Suite 1200

Houston, Texas 77098

Gail McIntyre <br> (via email: [\*\*\*\*])

February 1, 2023

Dear Gail:

Aravive, Inc. (the "<u>Company</u>") is pleased to enter into this amendment ("<u>Amendment</u>") to your Offer Letter, dated March 26, 2020, as amended on April 8, 2021 and January 25, 2021 (the "<u>Offer Letter</u>"), and hereby agrees to amend the Offer Letter as follows:

1. The first and second sentences of Section 3 are hereby deleted and replaced with the following:

"Effective as of February 1, 2023, the Company will pay you a salary at the rate of Five Hundred Sixty Thousand Dollars ($560,000) per year, less required deductions and withholdings, payable in accordance with the Company's standard payroll schedule. The salary will be subject to increase as determined by the Compensation Committee of the Board of Directors or the Board of Directors, in its discretion."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. All other terms of the Offer Letter shall remain in full force and effect. The Offer Letter, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. If any of the provisions of this Amendment are held to be invalid or unenforceable, the remaining provisions will nevertheless continue to be valid and enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. This Amendment is made and shall be construed and performed under the laws of the State of Texas without regard to its choice or conflict of law principles and the parties agree to the State of Texas as the exclusive venue for any disputes arising hereunder.

Very truly yours,

**Aravive Inc.**

---

| | |
|:---|:---|
| By: | /s/ Rudy Howard |

---

Name: Rudy Howard

Title: Chief Financial Officer

I have read and accept this amended employment offer:

/s/ Gail McIntyre

Signature

Printed Name: Gail McIntyre

Dated: February 6, 2023

## Exhibit 10.2

**Exhibit 10.2**

![aravive01.jpg](aravive01.jpg)

River Oaks Tower

3730 Kirby Drive, Suite 1200

Houston, Texas 77098

Rudy C. Howard

Via Email Delivery:

February 1, 2023

Dear Rudy:

Aravive, Inc. (the "<u>Company</u>") is pleased to enter into this amendment ("<u>Amendment</u>") to your Offer Letter, dated June 2, 2022 (the "<u>Offer Letter</u>"), and hereby agrees to amend the Offer Letter as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The first and second sentences of Section 3 are hereby deleted and replaced with the following:

"Effective as of February 1, 2023, the Company will pay you a salary at the rate of Four Hundred Twelve Thousand Seven Hundred Seventy-Five Dollars ($412,775) per year, less required deductions and withholdings, payable in accordance with the Company's standard payroll schedule. The salary will be subject to increase as determined by the Compensation Committee of the Board of Directors or the Board of Directors, in its discretion."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. All other terms of the Offer Letter shall remain in full force and effect. The Offer Letter, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. If any of the provisions of this Amendment are held to be invalid or unenforceable, the remaining provisions will nevertheless continue to be valid and enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. This Amendment is made and shall be construed and performed under the laws of the State of Texas without regard to its choice or conflict of law principles and the parties agree to the State of Texas as the exclusive venue for any disputes arising hereunder.

Very truly yours,

**Aravive Inc.**

---

| | |
|:---|:---|
| By: | /s/ Gail McIntyre |

---

Name: Gail McIntyre, Ph.D., DABT

Title: Chief Executive Officer

I have read and accept this amended employment offer:

/s/ Rudy Howard

Signature

Printed Name: Rudy Howard

Dated: February 6, 2023

## Exhibit 10.3

**Exhibit 10.3**

![aravive01.jpg](aravive01.jpg)

River Oaks Tower

3730 Kirby Drive, Suite 1200

Houston, Texas 77098

Robert B. Geller, M.D.

Via Email Delivery:

February 1, 2023

Dear Robert:

Aravive, Inc. (the "<u>Company</u>") is pleased to enter into this amendment ("<u>Amendment</u>") to your Offer Letter, dated June 13, 2022 (the "<u>Offer Letter</u>"), and hereby agrees to amend the Offer Letter as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The first and second sentences of Section 3 is hereby deleted and replaced with the following:

"Effective as of February 1, 2023, the Company will pay you a salary at the rate of Four Hundred Fifty Thousand Dollars ($450,000) per year, less required deductions and withholdings, payable in accordance with the Company's standard payroll schedule. The salary will be subject to increase as determined by the Compensation Committee of the Board of Directors or the Board of Directors."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. All other terms of the Offer Letter shall remain in full force and effect. The Offer Letter, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. If any of the provisions of this Amendment are held to be invalid or unenforceable, the remaining provisions will nevertheless continue to be valid and enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. This Amendment is made and shall be construed and performed under the laws of the State of Texas without regard to its choice or conflict of law principles and the parties agree to the State of Texas as the exclusive venue for any disputes arising hereunder.

Very truly yours,

**Aravive Inc.**

---

| | |
|:---|:---|
| By: | /s/ Gail McIntyre |

---

Name: Gail McIntyre, Ph.D., DABT

Title: Chief Executive Officer

I have read and accept this amended employment offer:

/s/ Robert Geller

Signature

Printed Name: Robert Geller, M.D.

Dated: February 6, 2023

## Exhibit 10.4

**Exhibit 10.4**

![aravive01.jpg](aravive01.jpg)

River Oaks Tower

3730 Kirby Drive, Suite 1200

Houston, Texas 77098

Leonard Scott Dove, Ph.D.

Via Email Delivery: [<u>\*\*\*\*]</u>

February 1, 2023

Dear Scott:

Aravive, Inc. (the "<u>Company</u>") is pleased to enter into this amendment ("<u>Amendment</u>") to your Offer Letter, dated February 20, 2022 (the "<u>Offer Letter</u>"), and hereby agrees to amend the Offer Letter as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The first and second sentences of Section 3 are hereby deleted and replaced with the following:

"Effective as of February 1, 2023, the Company will pay you a salary at the rate of Four Hundred Five Thousand Dollars ($405,000) per year, less required deductions and withholdings, payable in accordance with the Company's standard payroll schedule. The salary will be subject to increase as determined by the Compensation Committee of the Board of Directors or the Board of Directors, in its discretion."

2. All other terms of the Offer Letter shall remain in full force and effect. The Offer Letter, as amended by this Amendment, constitutes the entire agreement between the parties with respect to the subject matter thereof.

3. If any of the provisions of this Amendment are held to be invalid or unenforceable, the remaining provisions will nevertheless continue to be valid and enforceable.

4. This Amendment is made and shall be construed and performed under the laws of the State of Texas without regard to its choice or conflict of law principles and the parties agree to the State of Texas as the exclusive venue for any disputes arising hereunder.

Very truly yours,

**Aravive Inc.**

---

| | |
|:---|:---|
| By: | /s/ Gail McIntyre |

---

Name: Gail McIntyre, Ph.D., DABT

Title: Chief Executive Officer

I have read and accept this amended employment offer:

/s/ Leonard Scott Dove

Signature

Printed Name: Leonard Scott Dove, Ph.D.

Dated: February 6, 2023